« Back
Home /
Ruxolitinib

Ruxolitinib

Item no.	HY-50856-200mg
Manufacturer	MedChem Express
CASRN	941678-49-5
Amount	200 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 g 1 mg 200 mg 500 mg 50 mg 5 mg
Category	Food Safety Hormones Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.99
Citations	[1]Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117.\|[2]Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 2012, 366(9), 799-807.\|[3]Tavallai M, et al. Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic.Front Oncol. 2016 Jun 13;6:142. ACS Chem Biol. 2017 May 19;12(5):1245-1256.\|Acta Pharmacol Sin. 2020 Aug 27. \|Adv Sci (Weinh). 2021 Jan 6;8(5):2002738.\|AIDS. 2016 Aug 24;30(13):2053-64. \|Biochem Biophys Res Commun. 2020 May 7;525(3):662-667.\|Biochem Pharmacol. 2020 Aug;178:114103.\|Biomed Pharmacother. 2023 May 18;164:114902.\|Biomedicines. 2022 Apr 18;10(4):928. \|bioRxiv. 2021 Feb 5.\|bioRxiv. 2023 May 22.\|bioRxiv. 2024 August 08.\|bioRxiv. 2024 Dec 3:2024.11.27.625710.\|bioRxiv. 2025 February 21.\|bioRxiv. 2025 January 31.\|blood advances. 2018 Dec 11;2(23):3428-3442.\|Blood Sci. 2023 Jul 13.\|Blood. 2014 Dec 18;124(26):3924-31.\|Cancer Biol Ther. 2023 Dec 31;24(1):2269637.\|Cancer Cell Int. 2015 Mar 12;15:30. \|Cancer Commun (Lond). 2021 Dec;41(12):1354-1372.\|Cancer Discov. 2024 Jul 3.\|Cancer Immunol Res. 2025 Jan 9:OF1-OF19.\|Cancer Res. 2022 Nov 21;CAN-22-0423.\|Cancer Sci. 2021 Mar;112(3):997-1010.\|Cancers (Basel). 2023, 15(1), 296.\|Cancers (Basel). 2024 Apr 16, 16(8), 1511.\|Cancers (Basel). 2024 Apr 16;16(8):1511.\|Cell Biosci. 2021 Aug 4;11(1):156.\|Cell Cycle. 2020 Aug;19(16):2074-2080.\|Cell Death Dis. 2020 Nov 15;11(11):982.\|Cell Death Dis. 2022 May 25;13(5):496.\|Cell Death Dis. 2025 Jan 26;16(1):46.\|Cell Mol Biol Lett. 2024 Feb 2;29(1):22.\|Cell Mol Gastroenterol Hepatol. 2023 Oct 23:S2352-345X(23)00182-0.\|Cell Mol Immunol. 2022 Nov;19(11):1263-1278.\|Cell Mol Immunol. 2022 Oct;19(10):1130-1140.\|Cell Rep Med. 2024 Dec 3:101849.\|Cell Rep Med. 2024 Mar 19;5(3):101472.\|Cell Rep. 2020 Sep 15;32(11):108158.\|Cell Rep. 2023 Mar 30;42(4):112327.\|Cell Rep. 2024 Apr 23;43(4):114111.\|Cell Rep. 2024 Oct 11;43(10):114866.\|Cell Signal. 2025 Mar 2:131:111706.\|Cell Syst. 2018 Apr 25;6(4):424-443.e7.\|Cell. 2021 Apr 15;184(8):2167-2182.e22.\|Cell. 2024 Apr 25;187(9):2288-2304.e27.\|Chemosphere. 2021 Jan;263:127849.\|Clin Cancer Res. 2018 Apr 15;24(8):1917-1931.\|Clin Exp Dermatol. 2021 Feb 6.\|Clin Exp Immunol. 2021 Nov 27;207(1):113-122.\|Clin Exp Immunol. 27 November 2021.\|Columbia University. 2024.\|Cytojournal. 2024 Dec 20:21:69. \|Emerg Microbes Infect. 2023 Feb 7;2178238.\|Endocr Relat Cancer. 2023 Jun 1;ERC-23-0130.\|Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11.\|Eur J Pharmacol. 2022 Feb 11;920:174822.\|Exp Eye Res. 2021 Jan;202:108375.\|Exp Hematol. 2022 Mar 9;S0301-472X(22)00120-5.\|FEBS J. 2021 Nov 6.\|Front Oncol. 06 August 2021.\|Fundam Clin Pharmacol. 2021 Feb 1.\|Gut. 2020 Jan;69(1):122-132. \|Harvard Medical School. June 13, 2018\|Harvard University. 2024 May.\|Hemasphere. 2021 Aug 11;5(9):e630.\|Inflammation. 2025 Jan 13.\|Int Immunopharmacol. 2023 Jan 23;116:109723.\|Int Immunopharmacol. 2024 Dec 25:146:113817.\|Int Immunopharmacol. 2025 Jan 17:148:113972.\|Int J Biol Macromol. 2025 Jan 17:298:140025.\|Int J Clin Exp Pathol. 2017;10(3):3033-3042.\|Int J Med Microbiol. 2020 Oct;310(7):151450.\|Int J Mol Sci. 2022 Apr 12;23(8):4277.\|Int J Mol Sci. 2022 Dec 9;23(24):15646.\|Int J Mol Sci. 2022 May; 23(9): 5156.\|Int J Mol Sci. 2023 Apr 13, 24(8), 7219.\|Int J Mol Sci. 2023 May 25, 24(11), 9243.\|Invest New Drugs. 2022 Aug 31.\|iScience. 2021 Sep 25;24(10):103173.\|iScience. 2024 May 16.\|J Adv Res. 2022 Jul 13;S2090-1232(22)00156-4.\|J Agric Food Chem. 2015 Apr 8;63(13):3472-80. \|J Biol Chem. 2015 Nov 27;290(48):29022-34. \|J Cell Mol Med. 2020 Dec 12.\|J Cell Mol Med. 2022 Jun 10.\|J Clin Invest. 2021 Dec 15;131(24):e145501.\|J Exp Med. 2024 Jul 1;221(7):e20240111.\|J Exp Med. 2024 Mar 4;221(3):e20230683.\|J Exp Med. 2024 Mar 4;221(3):e20232028.\|J Leukoc Biol. 2022 May 19.\|J Med Virol. 2023 Nov;95(11):e29230.\|J Vet Sci. 2021 May;22(3):e39.\|J Virol. 2024 Jun 28:e0073824.\|JCI Insight. 2018 Sep 6;3(17). pii: 120750.\|JCI Insight. 2024 Oct 29:e173665.\|Kaohsiung J Med Sci. 2022 Nov 30.\|Leuk Lymphoma. 2022 Oct 12;1-8.\|Leukemia. 2012 Oct;26(10):2233-44.\|Leukemia. 2023 Mar 16.\|Metab Brain Dis. 2022 Dec 9.\|Mol Biol Rep. 2022 Nov 4.\|Mol Biol Rep. 2024 Jul 22;51(1):832.\|Mol Cell Biochem. 2024 Nov 5.\|Mol Genet Genomics. 2025 Feb 22;300(1):23.\|Nat Cancer. 2022 Sep;3(9):1071-1087.\|Nat Commun. 2021 Aug 13;12(1):4917.\|Nat Commun. 2023 Apr 24;14(1):2342.\|Nat Commun. 2023 May 10;14(1):2685.\|Nat Commun. 2024 Aug 26;15(1):7165.\|Nat Commun. 2024 Aug 6;15(1):6685.\|Nat Commun. 2024 Jan 10;15(1):446.\|Nat Med. 2018 Aug;24(8):1143-1150. \|Nature. 2022 Sep;609(7928):785-792.\|Nature. 2023 Mar;615(7950):158-167.\|Nature. 2025 Jan;637(8046):726-735. \|Neurotoxicology. 2024 Aug 27:S0161-813X(24)00100-1.\|Nutrients. 2019 Apr 5;11(4):791.\|Oncogenesis. 2019 Feb 22;8(3):15. \|Oncol Rep. 2018 Aug;40(2):635-646. \|Oncol Rep. 2024 May;51(5):71.\|Oncol Rep. 2025 Mar;53(3):40.\|Patent. US20180263995A1.\|Patent. US20210025893A1.\|Patent. US20220305048A1.\|PLoS Biol. 2023 Mar 17;21(3):e3002039.\|PLoS Genet. 2024 May 28;20(5):e1011293.\|PLoS One. 2017 Jun 30;12(6):e0180244.\|PLoS One. 2021 Sep 30;16(9):e0258140.\|PLoS One. 2022 Oct 14;17(10):e0276010.\|PLoS One. 2024 Nov 1;19(11):e0308647.\|Poultry Sci. 2021, 101085.\|Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2122512119.\|Proc Natl Acad Sci U S A. 2024 Nov 5;121(45):e2412725121.\|Res Sq. 2024 Jun 13.\|Research Square Preprint. 2023 Sep 11.\|Research Square Print. August 22nd, 2022.\|Ruperto Carola University Heidelberg. 2023 Jun 1.\|Sci Adv. 2024 Aug 9;10(32):eadn9519.\|Sci Adv. 2024 Mar 22;10(12):eadl0368.\|Sci Immunol. 2024 Jul 12;9(97):eadn0178.\|Sci Rep. 2021 Feb 15;11(1):3847.\|Sci Rep. 2024 Oct 10;14(1):23725.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Sci Transl Med. 2022 Aug 10;14(657):eabg3277.\|Signal Transduct Target Ther. 2024 Mar 9;9(1):65.\|SSRN. 2025 Feb 11.\|Talanta. 2020 Feb 1;208:120450.\|Theranostics. 2022 Oct 3;12(16):7051-7066.\|Université de Lausanne. 2024 Feb 7.\|University of Düsseldorf. 2024.\|University of Michigan. Cellular and Molecular Biology. 2022 Aug.\|University of Zürich. Department of Dermatology. 2021 Dec.\|Vet Microbiol. 2025 Feb 26:303:110444.\|Vet Microbiol. 29 October 2022, 109594.\|Virology. 2024 Sep 14:600:110245.\|Blood. 2013 Nov 21;122(22):3628-31.\|Cancer Discov. 2018 May;8(5):616-631.\|Haematologica. 2020 Jan;105(1):124-135. \|Harvard Medical School LINCS LIBRARY\|Inflamm Res. 2015 Jan;64(1):41-51. \|Int J Biol Macromol. 2021 Dec 2;194:153-162.\|J Hematol Oncol. 2021 Jun 24;14(1):97.\|N Engl J Med. 2024 May 30;390(20):1873-1884.\|Neuroscience. 2019 Dec 1;422:12-20.\|Oncotarget. 2017 Oct 4;8(55):94040-94053.
Smiles	N#CC[C@H](C1CCCC1)N2N=CC(C3=C4C=CNC4=NC=N3)=C2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	INCB18424
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Autophagy; JAK; Mitophagy
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	306.37
Product Description	Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3[1]. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy[3].
Manufacturer - Research Area	Cancer
Solubility	H2O: < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Isoform	JAK1; JAK2; JAK3; Tyk2
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-50856-200mg-safety-datasheet.pdf